Close Menu

NEW YORK − A retrospective study published in Nature Cancer last week found that circulating tumor DNA can be used to identify non-small cell lung cancer patients who might benefit from consolidation therapy with immune checkpoint inhibitors (ICI) after chemoradiation and to monitor their responses. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.